A Phase 1 interventional study of JNJ-26866138 0.7 mg/m2 and JNJ-26866138 1.0 mg/m2 in Multiple Myeloma, sponsored by Janssen Pharmaceutical K.K.. Completed at 28 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-12-02.
Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.
Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 49th largest by enrollment of the 267 interventional ones that give a count, is one of 22 that started in 2008, is one of 41 in phase 1, and was the 122nd registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
Canadian Myeloma Research Group · Sites in Canada
Ages 65+
Peking University First Hospital · Sites in China
Ages 18–70
Stichting European Myeloma Network · Sites in Austria, Germany, Greece and 2 more countries
Ages 18–70
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
271 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 76 · Phase 2 176 · Phase 3 46 · Phase 4 8
First in 1999; this study’s year is marked. 22 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 101 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 41 across the 267 interventional studies. Of the 194 that completed or were terminated, 94 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 271 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Pharmaceutical K.K., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 59th largest by enrollment of the 100 interventional ones that give a count, is one of 6 that started in 2008, is one of 24 in phase 1, and was the 31st registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
9 of the studies testing bortezomib in Multiple Myeloma that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT00734877Phase 3University of ArkansasUARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma | 2027-09 |
| NCT02718833Massachusetts General HospitalA Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | 2026-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 271 studies testing bortezomib in Multiple Myeloma, from their registry updates:
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of the study in Phase I is to select the recommended dose of bortezomib in combination with melphalan and prednisolone in Japanese participants. In Phase II, to assess the effectiveness and safety of the recommended dose of bortezomib (selected in the phase I portion).
This is an open-label (both physician and participant know the intervention), non-randomized (participants are not assigned by chance), multi-center study in untreated multiple myeloma participants who were not candidates for hematopoietic stem cell transplant. This study consists of two parts: Phase I and Phase II. In Phase I, a total of 18 participants will be enrolled ie, 6 patients per dose level (0.7, 1.0 and 1.3 mg/m2) to determine the recommended dose of bortezomib. In Phase II, additional 83 participants will be enrolled. Safety evaluations will include assessment of adverse events, clinical laboratory test, specifically hematological toxicities.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
JNJ-26866138 0.7 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles.
Drug: JNJ-26866138 0.7 mg/m2 · Drug: Melphalan · Drug: Prednisolone
JNJ-26866138 1.0 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
Drug: JNJ-26866138 1.0 mg/m2 · Drug: Melphalan · Drug: Prednisolone
JNJ-26866138 1.3 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
Drug: JNJ-26866138 1.3 mg/m2 · Drug: Melphalan · Drug: Prednisolone
JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5-9 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
Drug: JNJ-26866138 1.3 mg/m2 · Drug: Melphalan · Drug: Prednisolone
Drug page: Bortezomib
JNJ-26866138 0.7 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles.
Also known as: bortezomib
Drug page: Bortezomib
JNJ-26866138 1.0 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles
Also known as: bortezomib
Drug page: Bortezomib
Phase I: JNJ-26866138 1.3 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Phase II: JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5 to 9 cycles.
Also known as: bortezomib
Melphalan 9 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
Number of Participants With Dose Limiting Toxicity During the Phase I (Cycle 1)
Dose limiting toxicity defined as an adverse event or adverse drug reaction experienced by the participants during 6 weeks of treatment Cycle 1
Time frame: 6 weeks
Number of Participants With Overall Response (Complete Response [CR] + Partial Response [PR]) - Phase I and II
Response is evaluated as per the criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation (Blade et al. 1998). CR: disappearance of the original monoclonal protein from the blood and urine and \<5% plasma cells in the bone marrow on at least 2 determinations for a minimum of 6 weeks; no increase in the size or number of lytic bone lesions; disappearance of soft tissue plasmacytomas for at least 6 weeks. PR: ≥50% reduction in the level of serum monoclonal protein for at least 2 determinations 6 weeks apart; If present, reduction in 24-hour urinary light chain excretion by either ≥90% or to \<200 mg for at least 2 determinations 6 weeks apart; ≥50% reduction in the size of soft tissue plasmacytomas for at least 6 weeks; no increase in size or number of lytic bone lesions
Time frame: 54 weeks
Maximum Observed Plasma Concentration (Cmax) of Bortezomib (JNJ-26866138 Alone) - Phase I
Cmax of bortezomib following intravenous administration of JNJ-26866138 at dose of 0.7, 1.0, and 1.3 mg/m2 on Cycle 1/Day 25 (JNJ-26866138 alone)
Time frame: Day 25 of Cycle 1
Maximum Observed Plasma Concentration (Cmax) of Bortezomib (JNJ-26866138 in Combination With Melphalan and Prednisolone) - Phase I
Cmax of bortezomib following intravenous administration of JNJ-26866138 at dose of 0.7, 1.0, and 1.3 mg/m2 on Cycle 2/Day 4 (combination with melphalan and prednisolone)
Time frame: Day 4 of Cycle 2
Maximum Observed Plasma Concentration (Cmax) of Melphalan - Phase I
Cmax of melphalan at dose of 9 mg/m2 on Cycle 2/Day 4
Time frame: Day 4 of Cycle 2
Maximum Observed Plasma Concentration (Cmax) of Prednisolone - Phase I
Cmax of Prednisolone at dose of 60 mg/m2 on Cycle 2/Day 4
Time frame: Day 4 of Cycle 2
Median Time to First Response - Phase II
Time to first response is the duartion of time required to achieve first response to treatment
Time frame: up to 54 weeks
Total 101 participants (Phase I: 18 and Phase II: 83) were enrolled at multiple sites in Japan.
| Milestone | Phase I - JNJ-26866138 0.7 mg/m2 Group | Phase I - JNJ-26866138 1.0 mg/m2 Group | Phase I and II - JNJ-26866138 1.3 mg/m2 Group |
|---|---|---|---|
| Started | 6 | 6 | 87 |
| Completed | 3 | 3 | 28 |
| Not completed | 3 | 3 | 59 |
| Withdrew: Adverse event | 0 | 0 | 19 |
| Withdrew: Withdrawal by subject | 0 | 0 | 8 |
| Withdrew: Progressive disease | 1 | 2 | 8 |
| Withdrew: Unrecovered toxicity | 0 | 0 | 7 |
| Withdrew: Pneumonitis or pulmonary fibrosis | 2 | 0 | 2 |
| Withdrew: Complete response observed over 2 cycles | 0 | 1 | 4 |
| Withdrew: Other | 0 | 0 | 11 |
Dose limiting toxicity defined as an adverse event or adverse drug reaction experienced by the participants during 6 weeks of treatment Cycle 1
| Participants | Phase I - JNJ-26866138 0.7 mg/m2 Group | Phase I - JNJ-26866138 1.0 mg/m2 Group | Phase I - JNJ-26866138 1.3 mg/m2 Group |
|---|---|---|---|
| Number of Participants With Dose Limiting Toxicity During the Phase I (Cycle 1) | 0 | 0 | 1 |
Response is evaluated as per the criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation (Blade et al. 1998). CR: disappearance of the original monoclonal protein from the blood and urine and \<5% plasma cells in the bone marrow on at least 2 determinations for a minimum of 6 weeks; no increase in the size or number of lytic bone lesions; disappearance of soft tissue plasmacytomas for at least 6 weeks. PR: ≥50% reduction in the level of serum monoclonal protein for at least 2 determinations 6 weeks apart; If present, reduction in 24-hour urinary light chain excretion by either ≥90% or to \<200 mg for at least 2 determinations 6 weeks apart; ≥50% reduction in the size of soft tissue plasmacytomas for at least 6 weeks; no increase in size or number of lytic bone lesions
| Participants | Phase I - JNJ-26866138 0.7 mg/m2 Group | Phase I - JNJ-26866138 1.0 mg/m2 Group | Phase I - JNJ-26866138 1.3 mg/m2 Group | Phase II - JNJ-26866138 1.3 mg/m2 Group | Total |
|---|---|---|---|---|---|
| Number of Participants With Overall Response (Complete Response [CR] + Partial Response [PR]) - Phase I and II | 6 (54.1 to 100.0) | 5 (35.9 to 99.6) | 4 (28.4 to 99.5) | 60 (58.9 to 79.2) | 71 |
Cmax of bortezomib following intravenous administration of JNJ-26866138 at dose of 0.7, 1.0, and 1.3 mg/m2 on Cycle 1/Day 25 (JNJ-26866138 alone)
| ng/mL | Phase I - JNJ-26866138 0.7 mg/m2 Group | Phase I - JNJ-26866138 1.0 mg/m2 Group | Phase I - JNJ-26866138 1.3 mg/m2 Group |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Bortezomib (JNJ-26866138 Alone) - Phase I | 45.43 ± 10.087 | 59.42 ± 18.89 | 120.3 ± 24.527 |
Cmax of bortezomib following intravenous administration of JNJ-26866138 at dose of 0.7, 1.0, and 1.3 mg/m2 on Cycle 2/Day 4 (combination with melphalan and prednisolone)
| ng/mL | Phase I - JNJ-26866138 0.7 mg/m2 Group | Phase I - JNJ-26866138 1.0 mg/m2 Group | Phase I - JNJ-26866138 1.3 mg/m2 Group |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Bortezomib (JNJ-26866138 in Combination With Melphalan and Prednisolone) - Phase I | 34.40 ± 5.7986 | 69.50 ± 19.455 | 88.87 ± 19.568 |
Cmax of melphalan at dose of 9 mg/m2 on Cycle 2/Day 4
| ng/mL | Melphalan |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Melphalan - Phase I | 100.2 ± 49.515 |
Cmax of Prednisolone at dose of 60 mg/m2 on Cycle 2/Day 4
| ng/mL | Prednisolone |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Prednisolone - Phase I | 1131 ± 223.92 |
Time to first response is the duartion of time required to achieve first response to treatment
| Days | Phase II - JNJ-26866138 1.3 mg/m2 Group |
|---|---|
| Median Time to First Response - Phase II | 51 (43 to 82) |
Collected over 54 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I - JNJ-26866138 0.7 mg/m2 Group | — | 2/6 (33.3%) | 6/6 (100%) |
| Phase I - JNJ-26866138 1.0 mg/m2 Group | — | 2/6 (33.3%) | 6/6 (100%) |
| Phase I - JNJ-26866138 1.3 mg/m2 Group | — | 1/6 (16.7%) | 6/6 (100%) |
| Phase II - JNJ-26866138 1.3 mg/m2 Group | — | 29/87 (33.3%) | 87/87 (100%) |
| Event | Phase I - JNJ-26866138 0.7 mg/m2 Group | Phase I - JNJ-26866138 1.0 mg/m2 Group | Phase I - JNJ-26866138 1.3 mg/m2 Group | Phase II - JNJ-26866138 1.3 mg/m2 Group |
|---|---|---|---|---|
| GlaucomaEye disorders | 1/6 | 0/6 | 0/6 | 0/87 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 1/6 | 0/6 | 0/6 | 0/87 |
| RashSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 1/6 | 1/87 |
| Renal failureRenal and urinary disorders | 0/6 | 1/6 | 0/6 | 0/87 |
| PyrexiaGeneral disorders | 0/6 | 1/6 | 0/6 | 0/87 |
| Tumour lysis syndromeMetabolism and nutrition disorders | 0/6 | 0/6 | 0/6 | 2/87 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 2/87 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 2/87 |
| EnterocolitisGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 2/87 |
| Erythema multiformeSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 0/6 | 2/87 |
| Event | Phase I - JNJ-26866138 0.7 mg/m2 Group | Phase I - JNJ-26866138 1.0 mg/m2 Group | Phase I - JNJ-26866138 1.3 mg/m2 Group | Phase II - JNJ-26866138 1.3 mg/m2 Group |
|---|---|---|---|---|
| LeukopeniaBlood and lymphatic system disorders | 6/6 | 6/6 | 6/6 | 86/87 |
| LymphopeniaBlood and lymphatic system disorders | 6/6 | 6/6 | 6/6 | 86/87 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/6 | 6/6 | 5/6 | 86/87 |
| NeutropeniaBlood and lymphatic system disorders | 6/6 | 6/6 | 6/6 | 84/87 |
| DiarrhoeaGastrointestinal disorders | 2/6 | 3/6 | 6/6 | 56/87 |
| NauseaGastrointestinal disorders | 1/6 | 2/6 | 6/6 | 48/87 |
| PyrexiaGeneral disorders | 2/6 | 1/6 | 6/6 | 30/87 |
| Decreased appetiteMetabolism and nutrition disorders | 5/6 | 2/6 | 5/6 | 50/87 |
| Neuropathy peripheralNervous system disorders | 3/6 | 2/6 | 5/6 | 45/87 |
| ConstipationGastrointestinal disorders | 4/6 | 2/6 | 5/6 | 45/87 |
| Age Continuous(Years) | Phase I - JNJ-26866138 0.7 mg/m2 Group | Phase I - JNJ-26866138 1.0 mg/m2 Group | Phase I and II - JNJ-26866138 1.3 mg/m2 Group | Total |
|---|---|---|---|---|
| Mean | 72.7 ± 9.2 | 68.5 ± 6.47 | 70.9 ± 5.68 | 70.9 ± 5.94 |
| Age, Customized(Participants) | Phase I - JNJ-26866138 0.7 mg/m2 Group | Phase I - JNJ-26866138 1.0 mg/m2 Group | Phase I and II - JNJ-26866138 1.3 mg/m2 Group | Total |
|---|---|---|---|---|
| <65 years | 1 | 1 | 3 | 5 |
| >= 65 and <= 74 years | 2 | 5 | 60 | 67 |
| >=75 years | 3 | 0 | 24 | 27 |
| Sex: Female, Male(Participants) | Phase I - JNJ-26866138 0.7 mg/m2 Group | Phase I - JNJ-26866138 1.0 mg/m2 Group | Phase I and II - JNJ-26866138 1.3 mg/m2 Group | Total |
|---|---|---|---|---|
| Female | 3 | 3 | 51 | 57 |
| Male | 3 | 3 | 36 | 42 |
The record gives a start of Jul 2008, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bortezomib